Mallinckrodt Plc (MNKKQ) - Financial and Strategic SWOT Analysis Review

July 2021 | 60 pages | ID: MEFCA1430F1EN
GlobalData

Abstracts

Mallinckrodt Plc (MNKKQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mallinckrodt Plc (Mallinckrodt) develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy and neonatal respiratory critical care therapies; and analgesics and gastrointestinal products. The company offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Surrey, the UK.

Mallinckrodt Plc Key Recent Developments

Mar 19,2021: Mallinckrodt announces 2021 advancing extracorporeal photopheresis immunomodulation investigator award
Mar 10,2021: Mallinckrodt gains support for its restructuring support agreement from lenders holding approximately $1.3 billion of its first lien term loans
Feb 26,2021: Silence Therapeutics and Mallinckrodt initiate work on third target as part of ongoing RNAi research collaboration for complement-mediated diseases
Nov 16,2020: Mallinckrodt announces real world data on hepatorenal syndrome (HRS) and acute kidney injury (AKI) in patients with liver disease at The Liver Meeting Digital Experience
Oct 21,2020: Pharmaceutical giant Mallinckrodt bankruptcy threatens lawsuit filed by local unions and Delaware Valley Health Care Coalition, worth hundreds of millions of Dollars

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Mallinckrodt Plc - Key Facts
Mallinckrodt Plc - Key Employees
Mallinckrodt Plc - Key Employee Biographies
Mallinckrodt Plc - Major Products and Services
Mallinckrodt Plc - History
Mallinckrodt Plc - Company Statement
Mallinckrodt Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Mallinckrodt Plc - Business Description
Business Segment: Specialty Brands
Overview
Performance
Key Stats
Business Segment: Specialty Generics
Overview
Performance
Geographical Segment: Europe, Middle East and Africa
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Mallinckrodt Plc - Corporate Strategy
Mallinckrodt Plc - SWOT Analysis
SWOT Analysis - Overview
Mallinckrodt Plc - Strengths
Mallinckrodt Plc - Weaknesses
Mallinckrodt Plc - Opportunities
Mallinckrodt Plc - Threats
Mallinckrodt Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Mallinckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Mallinckrodt Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Mallinckrodt Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 19, 2021: Mallinckrodt announces 2021 advancing extracorporeal photopheresis immunomodulation investigator award
Mar 10, 2021: Mallinckrodt gains support for its restructuring support agreement from lenders holding approximately $1.3 billion of its first lien term loans
Feb 26, 2021: Silence Therapeutics and Mallinckrodt initiate work on third target as part of ongoing RNAi research collaboration for complement-mediated diseases
Nov 16, 2020: Mallinckrodt announces real world data on hepatorenal syndrome (HRS) and acute kidney injury (AKI) in patients with liver disease at The Liver Meeting Digital Experience
Oct 21, 2020: Pharmaceutical giant Mallinckrodt bankruptcy threatens lawsuit filed by local unions and Delaware Valley Health Care Coalition, worth hundreds of millions of Dollars
Oct 14, 2020: Mallinckrodt receives court approval of 'First Day' motions to support business operations
Oct 12, 2020: Mallinckrodt files for bankruptcy to resolve opioid claims
Aug 04, 2020: Mallinckrodt reports earnings for the second quarter 2020 and highlights pipeline advancements
Jul 09, 2020: Mallinckrodt to Report Earnings Results for Second Quarter 2020
Jun 10, 2020: Attorney General Tong leads coalition filing 3rd complaint in ongoing antitrust price-fixing investigation into generic drug industry

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Mallinckrodt Plc, Key Facts
Mallinckrodt Plc, Key Employees
Mallinckrodt Plc, Key Employee Biographies
Mallinckrodt Plc, Major Products and Services
Mallinckrodt Plc, History
Mallinckrodt Plc, Other Locations
Mallinckrodt Plc, Subsidiaries
Mallinckrodt Plc, Key Competitors
Mallinckrodt Plc, Ratios based on current share price
Mallinckrodt Plc, Annual Ratios
Mallinckrodt Plc, Annual Ratios (Cont...1)
Mallinckrodt Plc, Annual Ratios (Cont...2)
Mallinckrodt Plc, Interim Ratios
Mallinckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Mallinckrodt Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Mallinckrodt Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Mallinckrodt Plc, Performance Chart (2016 - 2020)
Mallinckrodt Plc, Ratio Charts
Mallinckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Mallinckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021